Cart
sales@molnova.com
Bimagrumab
CAS No. 1356922-05-8
Bimagrumab( —— )
Catalog No. M36745 CAS No. 1356922-05-8
Bimagrumab (BYM338) is a human monoclonal antibody that binds to the activin type II receptor. Bimagrumab can be used to study diabetes and obesity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 400 | Get Quote |
|
| 5MG | 629 | Get Quote |
|
| 10MG | 1007 | Get Quote |
|
| 25MG | 1444 | Get Quote |
|
| 50MG | 1950 | Get Quote |
|
| 100MG | 2574 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBimagrumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBimagrumab (BYM338) is a human monoclonal antibody that binds to the activin type II receptor. Bimagrumab can be used to study diabetes and obesity.
-
DescriptionBimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1356922-05-8
-
Formula WeightApproximately 142.78 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. ?
molnova catalog
related products
-
NSC 31152
NSC 31152 is a bioactive chemical.
-
Cauloside F
Cauloside F is a triterpenoid saponin isolated from?Clematis akebioides.
-
Omeprazole metabolit...
Omeprazole sulfone can inhibit proton pump.
